Berberine Inhibits the Disruption of the Blood–Brain Barrier and Glial Cell Activation in a Rat Model of Acute Hepatic Encephalopathy
Phytotherapy Research · 2025-03 · 39 (3) · 1422-1437
DOI: 10.1002/ptr.8430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 10.01.2025. Verfasst von Syed Afroz Ali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular NeuroTherapeutics, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Ra…. Hauptthemen laut MEDLINE: Hepatic Encephalopathy, Berberine, Blood-Brain Barrier, Neuroglia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India.
Abstract (Originalsprache)
Background and aim: Hepatic encephalopathy (HE) is a complex neurological disorder in individuals with liver diseases, necessitating effective neuroprotective interventions to alleviate its adverse outcomes. Berberine (BBR), a natural compound with well‐established anti‐fibrotic and neuroprotective properties, has not been extensively studied in the context of glial activation under hyperammonaemic conditions. This study evaluates the neuroprotective potential of BBR in a thioacetamide (TAA)‐induced HE rat model, focusing on its effects on glial activation and NLRP3 inflammasome signalling.
Methods
Neurological impairments were assessed using open field tests and sensory analysis. Western blotting was performed to evaluate the expression of glial and neuronal markers, tight junction proteins and NLRP3 inflammasome components in the cortex and hippocampus. Histopathological and molecular changes were further examined using H&E, immunohistochemistry and immunofluorescence staining. Key Results: BBR treatment significantly improved behavioural abnormalities and reduced systemic ammonia levels in TAA‐exposed rats. It restored blood–brain barrier integrity, as evidenced by reduced tight junction protein degradation. BBR inhibited the expression of NLRP3 inflammasome markers, including caspase‐1, IL‐1β, ASC, and NF‐κB, while reducing glial cell activation (IBA‐1 and GFAP). Notably, BBR diminished NLRP3 expression in glial cells, indicating its potent anti‐inflammatory effects. Additionally, BBR preserved neuronal integrity, as demonstrated by the maintained expression of MAP‐2 and NeuN and reduced cleaved Gasdermin D levels.
Conclusions
These findings suggest that BBR alleviates behavioural and molecular abnormalities in HE through NLRP3 inflammasome inhibition, highlighting its potential as a therapeutic agent for managing HE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular NeuroTherapeutics, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli, Uttar Pradesh, India.
- Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli, Uttar Pradesh, India.
ORCID-Profile: Ashok Kumar Datusalia
Förderung
- Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India
Zitieren
APA
Ali, S. A., & Datusalia, A. K. (2025). Berberine Inhibits the Disruption of the Blood–Brain Barrier and Glial Cell Activation in a Rat Model of Acute Hepatic Encephalopathy. Phytotherapy Research, 39(3), 1422-1437. https://doi.org/10.1002/ptr.8430
Vancouver
Ali SA, Datusalia AK. Berberine Inhibits the Disruption of the Blood–Brain Barrier and Glial Cell Activation in a Rat Model of Acute Hepatic Encephalopathy. Phytotherapy Research. 2025;39(3):1422-1437. doi:10.1002/ptr.8430
BibTeX
@article{Ali2025,
author = {Ali, Syed Afroz and Datusalia, Ashok Kumar},
title = {Berberine Inhibits the Disruption of the Blood–Brain Barrier and Glial Cell Activation in a Rat Model of Acute Hepatic Encephalopathy},
journal = {Phytotherapy Research},
year = {2025},
volume = {39},
number = {3},
pages = {1422--1437},
doi = {10.1002/ptr.8430}
}
EUVIMED